Abstracts - faqs.org

Abstracts

News, opinion and commentary

Search abstracts:
Abstracts » News, opinion and commentary

Microsoft cuts its projections for 4th quarter

Article Abstract:

Microsoft lowered earnings per share to 46 cents, on slowing growth of about 6 per cent. The sofware market leader revised revenue estimates from $6.5 bil to $6.4 bil. Fiscal year revenue is expected to top $25.5 bil. The announcement follows on similar announcements from Microsoft hardware partners like Dell, Intel, and Compaq. The company still sees strength in sales of its NT operating system.

Author: Feder, Barnaby J.
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2000
Prepackaged software, Computer Software, Software Publishers, Statistical Data Included, Computer software industry, Software industry, Software, Microsoft Corp., Forecasts and trends, MSFT

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Medical Devices Are Hot, Which Is Why Guidant Is

Article Abstract:

With the aging of the baby boomers, the demand for medical devices such as those made by Guidant Corp. is expected to grow by double digits. Both Boston Scientific Corp. and Johnson & Johnson have increased their bids to try to acquire Guidant.

Author: Feder, Barnaby J.
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2006
Acquisitions & mergers, Forecasts, trends, outlooks, Sales & consumption, Financial management, Industry Overview, Mergers, acquisitions and divestments, Finance, Company acquisition/merger, Company financing, Medical test kit industry, Industry sales and revenue, Guidant Corp., GDT, Industry forecasts

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


One Stent Maker Thrives as Rival Gets the Kudos

Article Abstract:

Boston Scientific's Taxus, a drug-coated stent, is leading the market in sales but evidence is mounting that Johnson and Johnson's similar product Cordis gives better patient results.

Author: Feder, Barnaby J.
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2004
Market information - general, Product information, Supply and demand, Stent (Surgery), Stents

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Company sales and earnings, Company earnings/profit, Pharmaceutical industry, Medical equipment and supplies industry, Medical equipment industry, Johnson & Johnson, JNJ, Boston Scientific Corp.
Similar abstracts:
  • Abstracts: Product development can fill prescription for success. CEO rises above severe dyslexia. An outside view of U.S. scandal, sky-high pay
  • Abstracts: Microsoft to refocus on users, Internet. Tires linked to 29 more deaths. Microsoft, Justice Department sparring
  • Abstracts: Retirees cite production practices. Hearings offer chance to vent, but little else. Firestone puts 'best theory' forward
  • Abstracts: Media powerhouses buy into new world order. AOL Time Warner receives tepid response to plans
  • Abstracts: GM dealers facing shortage of popular models. Airline revenue slumps as cheap seats abound
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.